A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors
2016
Oncoimmunology
Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to produce and deliver anticancer therapeutics that enhance cytotoxic T cell function and simultaneously inhibit immunosuppressive processes. Here, we review the potential of using T
doi:10.1080/2162402x.2015.1122158
pmid:27467930
pmcid:PMC4910704
fatcat:2iaiffcts5fzhdnvvy2ofmsqfu